The CRO success stories of the next decade will be the organizations that can keep up with the latest drug development trends and harness new technologies and regulations, and increased reliance on biomarkers seems to be the way forward.  Most pharma companies and smaller biotech companies have already embraced a biomarker approach to drug development, particularly in areas such as oncology, plus cardiovascular, metabolic, infectious and inflammatory diseases. (